Thermo Fisher Strengthens PCR Portfolio with $260M Fermentas Acquisition
May 27, 2010
Thermo Fisher Strengthens PCR Portfolio with $260M Fermentas Acquisition
Thomas Weisel Partners called Thermo Fisher's planned $260 million acquisition of Fermentas a "synergistic tuck-in deal" that "bolsters Thermo's capabilities in the high-growth PCR market."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Thermo Fisher Wraps up $260M Fermentas Acquisition
July 22, 2010 / PCR Insider - CDC Team Finds Widespread Murine Virus, Mouse DNA Contamination in Commercial PCR Reagents
January 5, 2012 / PCR Insider - IP Watch: Recent Patents Related to PCR, Nucleic Acid Amplification, and Sample Prep
October 14, 2010 / PCR Insider - Thermo Fisher Putting Pieces in Place to Tackle PCR-Based Testing Markets
June 3, 2010 / PCR Insider - With BioHelix Acquisition, Quidel Brings Isothermal Amplification Tech in House
May 9, 2013 / PCR Insider